These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. [Clonal evolution of myeloid malignancies]. Kon A Rinsho Ketsueki; 2020; 61(9):1120-1129. PubMed ID: 33162507 [TBL] [Abstract][Full Text] [Related]
28. Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms. Horiguchi H; Kobune M; Kikuchi S; Yoshida M; Murata M; Murase K; Iyama S; Takada K; Sato T; Ono K; Hashimoto A; Tatekoshi A; Kamihara Y; Kawano Y; Miyanishi K; Sawada N; Kato J Haematologica; 2016 Apr; 101(4):437-47. PubMed ID: 26802051 [TBL] [Abstract][Full Text] [Related]
29. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Mangan JK; Speck NA Crit Rev Oncog; 2011; 16(1-2):77-91. PubMed ID: 22150309 [TBL] [Abstract][Full Text] [Related]
30. A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination. Ideno N; Yamaguchi H; Okumura T; Huang J; Brun MJ; Ho ML; Suh J; Gupta S; Maitra A; Ghosh B Lab Invest; 2019 Jul; 99(8):1233-1244. PubMed ID: 30728464 [TBL] [Abstract][Full Text] [Related]
31. Targeted genome editing in acute lymphoblastic leukemia: a review. Montaño A; Forero-Castro M; Hernández-Rivas JM; García-Tuñón I; Benito R BMC Biotechnol; 2018 Jul; 18(1):45. PubMed ID: 30016959 [TBL] [Abstract][Full Text] [Related]
32. Relapse and cytogenetic evolution in myeloid neoplasms. Ertz-Archambault N; Kelemen K Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072 [TBL] [Abstract][Full Text] [Related]
33. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215 [TBL] [Abstract][Full Text] [Related]
34. [Pathophysiology of hematological malignancies associated with ASXL1 mutations]. Fujino T Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189 [TBL] [Abstract][Full Text] [Related]
35. JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells. Celik H; Koh WK; Kramer AC; Ostrander EL; Mallaney C; Fisher DAC; Xiang J; Wilson WC; Martens A; Kothari A; Fishberger G; Tycksen E; Karpova D; Duncavage EJ; Lee Y; Oh ST; Challen GA Cancer Cell; 2018 Nov; 34(5):741-756.e8. PubMed ID: 30423295 [TBL] [Abstract][Full Text] [Related]
36. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170 [TBL] [Abstract][Full Text] [Related]
39. Epigenetic regulation by ASXL1 in myeloid malignancies. Yang FC; Agosto-Peña J Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051 [TBL] [Abstract][Full Text] [Related]
40. Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models. Sano S; Wang Y; Evans MA; Yura Y; Sano M; Ogawa H; Horitani K; Doviak H; Walsh K J Vis Exp; 2019 Oct; (152):. PubMed ID: 31633690 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]